Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VBN
|
|||
| Drug Name |
CTX110
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1/2 | [1] | |
| Company |
CRISPR Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04035434) A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of CRISPR Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.